1Maggini M, Vanacore N, Raschetti R. Cholinesterase inhibitors: drugs looking for a disease[J] ? PLoS Med, 2006, 3(4) :e140.
2McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia[J]. Cochrane Database Syst Rev, 2006, 19(2) :CD003154.
3Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzhelmer's disease[J]. NeuroRx, 2005, 2(4) :612 -626.
4Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease [ J]. Neurology, 2006, 66(4) :602 -604.
6Chen F, Hasegawa H, Schmitt-Ulms G, et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity [ J ]. Nature, 2006, 440 ( 7088 ) : 1208 - 1212.
7Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation [ J ]. Nat Med, 2004, 10(10) :1065 - 1066.
8Ohno M, Chang L, Tseng W, et al. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1 [J]. Eur J Neurosci, 2006, 23(1) :251 -260.
9Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's- like pathology and behavior in human APP transgenic mice by mutation of Asp664 [ J]. Proc Natl Acad Sci USA, 2006, 103 (18) : 7130 - 7135.
10Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease[J]. Nat Rev Immunol, 2006, 6(5) : 404 -416.
